Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Quiflapon (MK-591) causes cell apoptosis. Quiflapon is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor (IC50: 1.6 nM in a FLAP binding assay) and is also an effective and orally active Leukotriene biosynthesis (LT) inhibitor (IC50: 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 53.00 | |
2 mg | In stock | $ 76.00 | |
5 mg | In stock | $ 101.00 | |
10 mg | In stock | $ 147.00 | |
25 mg | In stock | $ 337.00 | |
50 mg | In stock | $ 490.00 | |
100 mg | In stock | $ 728.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 157.00 |
Description | Quiflapon (MK-591) causes cell apoptosis. Quiflapon is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor (IC50: 1.6 nM in a FLAP binding assay) and is also an effective and orally active Leukotriene biosynthesis (LT) inhibitor (IC50: 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively). |
Targets&IC50 | FLAP:1.6 nM |
In vitro | Quiflapon is an effective inhibitor of leukotriene (LT) biosynthesis in the human, squirrel monkey, and rat whole blood (IC50: 510, 69, and 9 nM, respectively). Quiflapon has a high affinity for 5-lipoxygenase activating protein (FLAP) as evidenced by an IC50 value of 1.6 nM in a FLAP binding assay and inhibition of the photoaffinity labeling of FLAP by two different photoaffinity ligands. However, Quiflapon has no effect on rat 5-lipoxygenase. The inhibition of activation of 5-lipoxygenase was shown through inhibition of the translocation of the enzyme from the cytosol to the membrane in human PMNLs[1]. |
In vivo | Pups were treated with either vehicle or Quiflapon(10, 20, or 40 mg/kg; daily for days 1-4, 5-9, or 10-14) subcutaneously. On day 14, the lungs were inflated, fixed, and stained for histopathological and morphometric analyses. Inhibition of antigen-induced bronchoconstriction by Quiflapon is observed in inbred rats pretreated with methysergide, Ascaris-challenged squirrel monkeys, and Ascaris-challenged sheep (early and late phase response) [1]. Hyperoxia groups treated with Quiflapon untreated hyperoxia groups displayed definite evidence of aberrant alveolarization but no inflammation[2]. |
Synonyms | MK-591 |
Molecular Weight | 587.17 |
Formula | C34H35ClN2O3S |
CAS No. | 136668-42-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: ≥ 50 mg/mL (85.15 mM)
H2O: < 0.1 mg/mL (insoluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Quiflapon 136668-42-3 Apoptosis Immunology/Inflammation FLAP MK591 inhibit 5-LO activating protein MK 591 Inhibitor MK-591 inhibitor